Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Flux

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
European Journal of Nuclear Medicine and Molecular Imaging|February 12, 2013
EFOMP and EANM: joint recommendations for a curriculum for the education and training of physicists in nuclear medicineM N Lonsdale, M Bardiès, R Boellaard, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 31, 2017
Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?F Sun, G E Gerrard, J K Roberts, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 26, 2014
Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapyS Dizdarevic, R McCready, J F C Turner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2026
Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [<sup>177</sup>Lu]Lu-PSMA-617 therapyB J R Timmermans, B M Privé, R Hofferber, et al.
Annals of the ICRP|October 1, 2019
ICRP Publication 140: Radiological Protection in Therapy with RadiopharmaceuticalsY Yonekura, S Mattsson, G Flux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2017
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapyC Chiesa, K Sjogreen Gleisner, G Flux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 31, 2006
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to boneJ M O'Sullivan, A R Norman, V R McCready, et al.
British Journal of Cancer|June 28, 2002
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneJ M O'Sullivan, V R McCready, G Flux, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Journal of Nuclear Medicine and Molecular Imaging|February 12, 2013
EFOMP and EANM: joint recommendations for a curriculum for the education and training of physicists in nuclear medicineM N Lonsdale, M Bardiès, R Boellaard, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 31, 2017
Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?F Sun, G E Gerrard, J K Roberts, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 26, 2014
Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapyS Dizdarevic, R McCready, J F C Turner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2026
Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [<sup>177</sup>Lu]Lu-PSMA-617 therapyB J R Timmermans, B M Privé, R Hofferber, et al.
Annals of the ICRP|October 1, 2019
ICRP Publication 140: Radiological Protection in Therapy with RadiopharmaceuticalsY Yonekura, S Mattsson, G Flux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2017
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapyC Chiesa, K Sjogreen Gleisner, G Flux, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 31, 2006
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to boneJ M O'Sullivan, A R Norman, V R McCready, et al.
British Journal of Cancer|June 28, 2002
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneJ M O'Sullivan, V R McCready, G Flux, et al.
Pageof 2